Its actually three distinct consumer logics sharing a common rejection of Consumption as Experience in favor of Consumption as Calibration. Understanding which logic youre dealing with determines your product strategy
Accessed January 2026
Outcomes at one year can be comparable to the injectable when the daily protocol is followed consistently - the variable is adherence, not the drug itself
Medications like orforglipron (an oral, non-peptide GLP-1 agonist), survodutide (a dual glucagon/GLP-1 agonist), and CagriSema (combining cagrilintide with semaglutide) are advancing through clinical trials
It is not a pharmacogenomic test and never predicts drug response it gives you and your provider upstream context before you commit to any price
Per the FDA meeting notice, the agency reviewed each peptide for a narrow use: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTS-c for obesity and osteoporosis